GLP-1 Market
LLY $1137.82 ▲ +0.2% NVO $41.71 ▼ -1.9% PFE $27.46 ▼ -0.3% VKTX $29.52 ▼ -1.4% KLRA $12.70 ▼ -5.6% GPCR $35.50 ▼ -8.9% RHHBY $55.15 ▲ +0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Fixed-Dose Combination Strategy

Company
China Medical University, China
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
4 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

4 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for Fixed-Dose Combination Strategy and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05963568

    Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)

    Not yet reported Northern California Institute of Research and Education 1000 participants Est. completion 2029-02-01 4 sites
    Cardiovascular disease Other conditions: Medication Adherence
    View official trial listing →
  • Recruiting NCT NCT06143566

    Polypill for Prevention of Cardiomyopathy

    Not yet reported, Not yet reported University of Texas Southwestern Medical Center 200 participants Est. completion 2027-12-01 1 site
    Type 2 diabetes Other conditions: High Blood Pressure
    View official trial listing →
  • Recruiting NCT NCT07032389

    A Polypill for Acute Coronary Syndrome

    Not yet reported University of Texas Southwestern Medical Center 1000 participants Est. completion 2030-07-31 2 sites
    Other conditions: Acute Coronary Syndrome
    View official trial listing →
  • Recruiting NCT NCT07679828

    Polypills Approach for Multiple Cardiovascular Risk Factors

    Not yet reported China Medical University, China 8252 participants Est. completion 2030-03-01 15 sites Stand-alone
    Other conditions: Hypertension, Dyslipidemia, Diabetes
    View official trial listing →
  • Completed NCT NCT04633005

    Polypill Strategy for Heart Failure With Reduced Ejection Fraction

    Not yet reported University of Texas Southwestern Medical Center 212 participants Est. completion 2025-10-31 1 site
    Heart failure
    View official trial listing →
  • Completed NCT NCT05514938

    Polypill in Acute Coronary Syndrome

    Not yet reported University of Texas Southwestern Medical Center 140 participants Est. completion 2025-06-05 1 site
    Cardiovascular disease Other conditions: Acute Coronary Syndrome, Lipid Disorder
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Fixed-Dose Combination Strategy, Polypill Strategy

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.